News
England appoints Women’s Health Ambassador to tackle gender health gap
The Women’s Health Ambassador will support the implementation of the upcoming women’s health strategy
Women’s health and care will be improved following the appointment of Dame Lesley Regan as the government’s first ever Women’s Health Ambassador for England.
The strategy aims to tackle the gender health gap and ensure services meet the needs of women throughout their life. Bringing with her a raft of expertise spanning a 42-year career in women’s health, Dame Lesley Regan will support the implementation of the upcoming women’s health strategy.
She will continue in her role as Professor of Obstetrics and Gynaecology at Imperial College London St Mary’s Hospital Campus, and remains in active clinical practice.
“Having spent my career working with and caring for women, it is a great honour to be appointed as Women’s Health Ambassador for the first government-led women’s health strategy in England,” she said.
“This is an important opportunity to get it right for women and girls, and make a real difference to 51 per cent of our population by addressing the inequalities that exist across society. I look forward to working with women, girls, health services, charities, policy makers, the government and other key partners to implement this strategy.”
Health and Social Care Secretary, Sajid Javid, said: “The healthcare system needs to work for everyone, and I am committed to tacking inequalities which exist within it, particularly for women.
“Closing the gender health gap is critical for a fair health and care system in the future. I look forward to working closely with Dame Lesley on our shared mission to ensure all women feel listened to by the health and care system and are able to access the support and services they need.”
Closing the gender health gap is vital to the government’s wider levelling up ambition. A lack of support, awareness and understanding of health conditions specific to women can be harmful not only to the health and happiness of women, but the health of the economy.
One in four women consider leaving their job as a result of the menopause, and ensuring women have the right support in place to stay in the workplace for longer will not only enable them to live fulfilled lives, but help to boost the economy and help tackle the rising costs of living.
The Civil Service recently signed the Wellbeing of Women Menopause Workplace Pledge, committing to ensuring those going through the menopause are supported.
Dame Lesley will be instrumental in driving forward the system-level changes needed to close the gender health gap and eradicating deep seated biases.
“Since we launched our Women’s Health call for evidence over a year ago, we have made great progress in raising the profile of women’s health,” said Maria Caulfield, Minister for Women’s Health. “From the formation of the UK-wide menopause taskforce and publication of our vision document, to legislating to ban hymenoplasty and virginity testing and appointing a chair of the HRT taskforce to help more menopausal women access this lifeline medication.
“The appointment of Dame Lesley as the Women’s Health Ambassador for England is yet another step in the right direction to giving women’s health the platform and profile it needs.”
She added that: “We are embarking on an important journey to eradicate the gender health gap. There is no quick fix. But I look forward to working together with Dame Lesley as we take the next steps to implement our women’s health strategy and beyond.”
The appointment of Dame Lesley will be followed by the appointment of a deputy ambassador who will work closely with her and be responsible for increasing awareness of the women’s health strategy and its ambitions, better understanding the barriers and issues of concern of under-served groups of women and girls.
This is the latest step taken by the government to ensure women’s healthcare needs are met. This includes taking action to increase access and reduce the cost of HRT meaning women can pay a one-off charge equivalent to two single prescription charges, currently £18.70, for all their HRT prescriptions for a year.
The government hopes that the creation of a prepayment certificate will mean women can access HRT on a month-by-month basis if need be, easing pressure on supply, while keeping the cost of HRT low. The system will be implemented by April 2023.
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.
The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.
Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.
Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.
Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.
“This is critical and hopefully can help mothers prepare accordingly.”
The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.
Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.
The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.
The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.
“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.
“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”
The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.
Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.
“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.
“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”
Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.
The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.
Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.
The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.
Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.
David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.
“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”
Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.
A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.
Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.
Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.
Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.
Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.
Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.
AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.
Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.
AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.
In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health